

Lupin receives FDA approval for Fluocinonide Topical Solution

26 July 2017 | News

It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses



Pharma Major Lupin Limited recently announced that it has received final approval for its Fluocinonide Topical Solution USP, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of County Line Pharmaceuticals, LLC's Fluocinonide Topical Solution USP, 0.05%.

Lupin's Fluocinonide Topical Solution USP, 0.05% is AT rated generic equivalent of County Line Pharmaceuticals, LLC's Fluocinonide Topical Solution USP, 0.05%.

It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.